论文部分内容阅读
目的:探讨复方鳖甲软肝片对肝癌患者肝动脉化疗栓塞术(TACE)后纤维化指标及疗效的影响。方法:56例患者随机分为两组各28例,均接受化疗药TACE术,手术间隔时间为1个月,共行3次手术,对照组予水飞蓟宾葡甲胺片保肝治疗,治疗组在此基础上加用复方鳖甲软肝片,3个月一疗程。治疗前后测定肝纤维化指标(HA、LN、PCⅢ、ⅣC)、肿瘤大小,术后评定疗效,随访生存率。结果:治疗后,两组肿瘤直径均较治疗前显著缩小,差异无统计学意义(P>0.05);两组患者纤维化指标HA、LN、PCⅢ、ⅣC均有不同程度升高(P<0.05或0.01),治疗组各指标均较对照组偏低(P<0.01);两组临床有效率、临床控制率6个月和1年生存率等指标比较,差异无统计学意义(P>0.05)。结论:复方鳖甲软肝片可明显改善肝癌患者TACE术后减轻纤维化程度。
Objective: To investigate the effect of Fufang Biejiarangan Tablets on fibrosis index and therapeutic effect after transcatheter arterial chemoembolization (TACE) in patients with liver cancer. Methods: Fifty-six patients were randomly divided into two groups of 28 patients, all receiving chemotherapy TACE, the operation interval was 1 month, a total of 3 operations, the control group to silybin meglumine tablets liver protection, On the basis of the treatment group, compound Biejia Ruangan tablet was added to the treatment group for three months and one course of treatment. The indexes of liver fibrosis (HA, LN, PC Ⅲ, Ⅳ C) before and after treatment, the size of the tumor, the curative effect after operation, and the follow-up survival rate. Results: After treatment, the tumor diameter of both groups was significantly reduced compared with that before treatment, with no significant difference (P> 0.05). The fibrosis indexes of HA, LN, PCⅢ and ⅣC in both groups were increased to some extent (P <0.05 Or 0.01). The indexes in the treatment group were lower than those in the control group (P <0.01). There was no significant difference in clinical effective rate, clinical control rate at 6 months and 1-year survival rate between the two groups (P> 0.05 ). Conclusion: Fufang Biejia Ruangan Pian can significantly improve the degree of fibrosis in patients with liver cancer after TACE.